- Home
- CMBM vs RPHM Comparison
CMBM vs RPHM Comparison
Compare CMBM & RPHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBM
- RPHM
- Stock Information
- Founded
- CMBM 2011
- RPHM 2014
- Country
- CMBM United States
- RPHM United States
- Employees
- CMBM N/A
- RPHM N/A
- Industry
- CMBM Radio And Television Broadcasting And Communications Equipment
- RPHM Biotechnology: Pharmaceutical Preparations
- Sector
- CMBM Technology
- RPHM Health Care
- Exchange
- CMBM Nasdaq
- RPHM Nasdaq
- Market Cap
- CMBM 50.8M
- RPHM 47.5M
- IPO Year
- CMBM 2019
- RPHM 2021
- Fundamental
- Price
- CMBM $1.64
- RPHM $1.82
- Analyst Decision
- CMBM Buy
- RPHM Hold
- Analyst Count
- CMBM 6
- RPHM 6
- Target Price
- CMBM $6.13
- RPHM $2.26
- AVG Volume (30 Days)
- CMBM 59.3K
- RPHM 344.7K
- Earning Date
- CMBM 10-31-2024
- RPHM 11-11-2024
- Dividend Yield
- CMBM N/A
- RPHM N/A
- EPS Growth
- CMBM N/A
- RPHM N/A
- EPS
- CMBM N/A
- RPHM N/A
- Revenue
- CMBM $171,535,000.00
- RPHM N/A
- Revenue This Year
- CMBM N/A
- RPHM N/A
- Revenue Next Year
- CMBM $19.77
- RPHM N/A
- P/E Ratio
- CMBM N/A
- RPHM N/A
- Revenue Growth
- CMBM N/A
- RPHM N/A
- 52 Week Low
- CMBM $1.52
- RPHM $0.98
- 52 Week High
- CMBM $6.50
- RPHM $9.21
- Technical
- Relative Strength Index (RSI)
- CMBM 41.19
- RPHM 69.89
- Support Level
- CMBM $1.71
- RPHM $1.61
- Resistance Level
- CMBM $1.84
- RPHM $1.75
- Average True Range (ATR)
- CMBM 0.13
- RPHM 0.13
- MACD
- CMBM -0.01
- RPHM 0.04
- Stochastic Oscillator
- CMBM 6.38
- RPHM 87.30
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About RPHM Reneo Pharmaceuticals Inc.
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.